Scilex Holding Company stock is traded at $0.5658, with a volume of 198,252. It is down -12.95% in the last 24 hours and down -77.64% over the past month. Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Previous Close:
$0.65
Open:
$0.613
24h Volume:
198,252
Relative Volume:
1.40
Market Cap:
$3.98M
Revenue:
$33.86M
Net Income/Loss:
-$437.38M
P/E Ratio:
-
EPS:
-$40.58
Net Cash Flow:
-$42.07M
1W Performance:
-60.43%
1M Performance:
-77.64%
6M Performance:
-90.59%
1Y Performance:
-97.01%
1-Day Range:
$0.5$0.6305
1-Week Range:
$0.5$1.39
52-Week Range:
$0.5$27.00
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding CompanySector
HealthcareIndustry
Drug Manufacturers - GeneralPhone
(650) 516-4310Address
960 SAN ANTONIO ROAD, PALO ALTO, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS